微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > peripheral T-cell lymphoma
peripheral T-cell lymphoma

肿瘤

关键词肿瘤 疾病 淋巴瘤

词汇介绍

拓展阅读

解析

Peripheral   英 /pə'rɪf(ə)r(ə)l/   美 /pə'rɪfərəl/

释    义   adj. 外围的;次要的;(神经)末梢区域的;n. 外部设备

同根词   peripherally adv. 周边地;外围地;次要地;periphery n. 外围,边缘;圆周;圆柱体表面

例    句   Objective:To study the application and significance of making chromosome specim peripheral blood lymphocyte(PBL) by large volume culture for students experiment. 目的: 探讨大体积培养人外周血淋巴细胞(PBL)染色体标本技术在学生实验中的应用及意义。

 

Lymphoma   英 /lɪm'fəʊmə/   美 /lɪm'fomə/

释    义   n. [肿瘤] 淋巴瘤;复数 lymphomas或lymphomata

同根词   lymphatic adj. 淋巴的;含淋巴的;lymphocytic adj. 淋巴细胞的;淋巴球的;lymphatic n. 淋巴管;淋巴腺;lymphocytosis n. 淋巴球增多;淋巴球过多症;lymphopoiesis n. 淋巴组织生成;淋巴细胞增殖

例    句   No two people with leukemia, lymphoma or myeloma are alike, nor are any two relatives or friends of someone with one of these illnesses the same. 没有任何两个白血病、淋巴瘤或者骨髓瘤的患者是完全相同的,同样,他们的亲戚朋友也不会。

概述

外周T细胞淋巴瘤,简称PTCL,是一组高度异质性的淋巴细胞异常恶性增殖性疾病。在我国,PTCL的病例占非霍奇金淋巴瘤25%~30%,显著高于欧美国家的10%-15%。据2008年WHO造血与淋巴组织肿瘤的分类标准,PTCL共包含22个亚型。我国最常见的亚型为结外NK/T 细胞淋巴瘤(鼻型);PTCL-非特指型;T 淋巴母细胞性淋巴瘤/白血病等。这些都属于外周T细胞淋巴瘤的范畴,无论是查询治疗方法还是最新动态都归类在PTCL中。 临床特征PTCL常见的临床表现为全身淋巴结肿大和/或结

ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY复制标题

PTCL患者口服5-氮杂胞苷和罗米地辛表现出明显的活性: 一项多中心I期研究

发表时间:2019-08-30

影响因子:16.6

作者: Owen A. O’Connor

期刊:Blood

The peripheral T-cell lymphoma (PTCL) are uniquely sensitive to epigenetic modifiers. Based on the synergism between histone deacetylase (HDAC) inhibitors and hypomethylating agents we established in preclinical PTCL models, we conducted a phase 1 study of oral 5-azacytidine (AZA) and romidepsin (ROMI) in patients with advanced lymphoid malignancies, with emphasis on PTCL. Following a 3 + 3 design patients were assigned to one of seven cohorts with AZA doses ranging from 100 mg daily on days 1-14 to 300 mg daily on days 1-21, ROMI doses ranging from 10 mg/m2 on days 8 and 15, to 14 mg/m2 on days 8, 15, and 22, and cycles of 21 to 35 days. Co-primary endpoints included maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). We treated a total of 31 patients. The MTD was AZA 300 mg on days 1-14 and ROMI 14 mg/m2 on days 8, 15 and 22 on a 35-day cycle. DLTs included grade 4 thrombocytopenia, prolonged grade 3 thrombocytopenia, grade 4 neutropenia, and pleural effusion. There were no treatment-related deaths. The combination was substantially more active in patients with PTCL than non-T-cell lymphoma.

译文

外周T细胞淋巴瘤(PTCL)对表观遗传修饰因子特别敏感。基于我们在临床前PTCL模型中建立的组蛋白脱乙酰基酶(HDAC)抑制剂和次甲基化剂之间的协同作用,我们对晚期淋巴恶性肿瘤患者的口服5-氮杂胞苷(AZA)和罗米地辛(ROMI)进行了1期研究,重点是PTCL。经过3 + 3设计后,将患者分为7组中的一组,AZA剂量范围从1-14天每天100 mg至1-21天每天300 mg,ROMI剂量在8天和15天范围从10 mg / m2在第8、15和22天达到14 mg / m2,周期为21到35天。共同主要终点包括最大耐受剂量(MTD)和剂量限制毒性(DLT)。我们共治疗了31名患者。在35天的周期中,MTD在第1-14天为AZA 300 mg,在第8、15和22天为ROMI 14 mg / m2。 DLTs包括4级血小板减少,3级血小板减少,4型中性白细胞减少和胸腔积液。没有与治疗有关的死亡。与非T细胞淋巴瘤相比,该组合在PTCL患者中的活性明显更高。